0001628280-26-009470
SEC filingKoninklijke Philips N.V. reported solid financial results for FY 2025, with sales of $17.83 billion and net income attributable to shareholders of $895 million. The company generated a gross margin of $8.06 billion (45.2% gross margin) and operating income of $1.42 billion (8.0% operating margin). Cash flow from operations was strong at $1.17 billion, though free cash flow was impacted by capital expenditures. The balance sheet shows total assets of $26.94 billion with group equity of $10.99 billion and total liabilities of $15.95 billion, including $8.08 billion in total debt. The company maintained a healthy cash position of $2.79 billion while paying $328 million in dividends to shareholders. These results demonstrate the company's ability to generate profitability and cash flow while maintaining financial stability.
Koninklijke Philips N.V. reported FY 2025 sales of $17.83 billion with cost of sales of $9.78 billion, resulting in gross profit of $8.06 billion. The company generated operating income of $1.42 billion after selling expenses of $4.34 billion, general and administrative expenses of $628 million, and research and development expenses of $1.70 billion. Net income was $897 million, with $895 million attributable to shareholders and $1 million to non-controlling interests. Basic earnings per share were $1 for both continuing operations and total operations. The company maintained strong cash generation with operating cash flow of $1.17 billion.
The filing provides consolidated revenue figures without segment breakdown. Sales of $17.83 billion represent the company's total revenue from continuing operations. No geographic or segment-level revenue data is disclosed in the provided financial statements. The company's revenue generation appears stable, supported by its diversified healthcare and consumer product portfolio. The absence of segment disclosure limits detailed analysis of revenue drivers and growth patterns across different business units.
The company achieved a gross margin of 45.2% ($8.06 billion gross profit on $17.83 billion sales). Operating margin was 8.0% ($1.42 billion operating income on $17.83 billion sales). Selling expenses represented 24.3% of sales, while research and development accounted for 9.5% of sales. The net profit margin was 5.0% ($897 million net income on $17.83 billion sales). These margins reflect the company's cost structure and profitability profile, with significant investment in sales and marketing alongside research and development activities.
Operating cash flow was strong at $1.17 billion, driven by net income of $897 million and adjustments including depreciation of $1.12 billion. Investing activities used $737 million, primarily for capital expenditures of $660 million. Financing activities provided $107 million, with $1.06 billion in long-term debt issuance offset by $609 million in debt repayments and $328 million in dividends. Free cash flow (operating cash flow minus capital expenditures) was $510 million. The balance sheet shows total assets of $26.94 billion, including $9.27 billion in goodwill and $2.79 billion in cash. Total debt stands at $8.08 billion ($6.93 billion long-term, $1.15 billion short-term) against group equity of $10.99 billion.
The filing does not contain forward-looking statements, management guidance, or specific strategic priorities in the provided financial data sections. No risk factors or future outlook information is included in the extracted financial statements. Investors should refer to the complete 20-F filing for management discussion and analysis, risk factors, and forward-looking statements that typically accompany these financial results in the full document.